These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7232835)

  • 1. DNA, liposomes, and proteins as carriers for antitumoral drugs.
    Trouet A; Baurain R; Deprez-De Campeneere D; Layton D; Masquelier M
    Recent Results Cancer Res; 1980; 75():229-35. PubMed ID: 7232835
    [No Abstract]   [Full Text] [Related]  

  • 2. Antibodies as carriers for oncostatic materials.
    Arnon R; Hurwitz E; Sela M
    Recent Results Cancer Res; 1980; 75():236-45. PubMed ID: 6165055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experimental methods in cancer therapeutics.
    Widder KJ; Senyei AE; Sears B
    J Pharm Sci; 1982 Apr; 71(4):379-87. PubMed ID: 7045329
    [No Abstract]   [Full Text] [Related]  

  • 4. [Experimental affinity chemotherapy in cancer].
    Chen GJ; Wang SZ
    Sheng Li Ke Xue Jin Zhan; 1986 Apr; 17(2):154-9. PubMed ID: 2431479
    [No Abstract]   [Full Text] [Related]  

  • 5. [Liposome encapsulation as a possibility for the improvement of tumor chemotherapy].
    Fichtner I; Reszka R; Elbe B; Arndt D
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(5):658-63. PubMed ID: 6172330
    [No Abstract]   [Full Text] [Related]  

  • 6. Liposomes as lysosomotropic carriers.
    de Duve C; Trouet A; Campeneere DD; Baurian R
    Ann N Y Acad Sci; 1978; 308():226-34. PubMed ID: 279290
    [No Abstract]   [Full Text] [Related]  

  • 7. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.
    Drummond DC; Meyer O; Hong K; Kirpotin DB; Papahadjopoulos D
    Pharmacol Rev; 1999 Dec; 51(4):691-743. PubMed ID: 10581328
    [No Abstract]   [Full Text] [Related]  

  • 8. [Biological properties of antineoplastic drugs linked with macromolecular vehicles].
    Boratyński J
    Postepy Hig Med Dosw; 1980; 33(6):613-24. PubMed ID: 6992129
    [No Abstract]   [Full Text] [Related]  

  • 9. In vivo enhancement of the experimental oncostatic effect of RFCNU by its encapsulation in liposomes.
    Mathé G; Bothorel P
    Biomedicine; 1981 Dec; 35(7-8):201-2. PubMed ID: 7346064
    [No Abstract]   [Full Text] [Related]  

  • 10. Potential applications of liposomes to therapy.
    Ryman BE; Jewkes RF; Jeyasingh K; Osborne MP; Patel HM; Richardson VJ; Tattersall MH; Tyrrell DA
    Ann N Y Acad Sci; 1978; 308():281-307. PubMed ID: 358897
    [No Abstract]   [Full Text] [Related]  

  • 11. Potential of liposomes as drug-carriers in cancer chemotherapy: a review.
    Kaye SB; Richardson VJ
    Cancer Chemother Pharmacol; 1979; 3(2):81-5. PubMed ID: 389479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carrier-based strategies for targeting protein and peptide drugs to the lungs.
    Cryan SA
    AAPS J; 2005 Mar; 7(1):E20-41. PubMed ID: 16146340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomes as drug carriers in cancer therapy: hyperthermia and pH sensitivity as modalities for targeting.
    Yatvin MB; Cree TC; Tegmo-Larsson IM; Gipp JJ
    Strahlentherapie; 1984 Dec; 160(12):732-40. PubMed ID: 6393456
    [No Abstract]   [Full Text] [Related]  

  • 14. [Studies of the possibilities of the use of serum albumin as a transporter of antitumoral agents].
    Cerottini JC; Isliker H
    Helv Physiol Pharmacol Acta; 1966; 24(2):C13-6. PubMed ID: 5973812
    [No Abstract]   [Full Text] [Related]  

  • 15. The liposomal daunorubicin plus tamoxifen: improving the stability, uptake, and biodistribution of carriers.
    Shao M; Sun SL; Li MH; Li BX; Yu H; Shen ZY; Ren YC; Hao ZF; Chang ND; Peng HS; Yang BF
    J Liposome Res; 2012 Jun; 22(2):168-76. PubMed ID: 22428938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting of daunorubicin by association with DNA or proteins: a review.
    Trouet A; Jollès G
    Semin Oncol; 1984 Dec; 11(4 Suppl 3):64-72. PubMed ID: 6095457
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting therapy with mitosomal daunorubicin plus amlodipine has the potential to circumvent intrinsic resistant breast cancer.
    Zhang Y; Li RJ; Ying X; Tian W; Yao HJ; Men Y; Yu Y; Zhang L; Ju RJ; Wang XX; Zhou J; Chen JX; Li N; Lu WL
    Mol Pharm; 2011 Feb; 8(1):162-75. PubMed ID: 21062083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical anticancer pharmacology: some pharmacokinetic considerations.
    Levin VA
    Cancer Treat Rev; 1986 Jun; 13(2):61-76. PubMed ID: 3755652
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-carrier potential of liposomes in cancer chemotherapy.
    Gregoriadis G; Wills EJ; Swain CP; Tavill AS
    Lancet; 1974 Jun; 1(7870):1313-6. PubMed ID: 4134296
    [No Abstract]   [Full Text] [Related]  

  • 20. Drug targeting in cancer treatment: active daunorubicin-protein conjugates.
    Deprez-de Campeneere D; Masquelier M; Baurain R; Trouet A
    Prog Clin Biol Res; 1982; 102 pt A():291-8. PubMed ID: 7167441
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.